National Pharmaceuticals Corp
PINK SHEETS : NFRM

April 06, 2011 00:31 ET

National Pharmaceuticals Lead Therapeutic Drug, GLB333 Application in Lupus

MIAMI, FLORIDA--(Marketwire - April 6, 2011) - National Pharmaceuticals Corp. (PINK SHEETS:NFRM) or the "Company" is pleased to announce that its partner, Globe Laboratories concluded that GLB333, the Company's Lead Therapeutic drug may have effect in the treatment of Lupus. Lupus complications are caused by over expression of certain cytokine (interleukins) according to several scientific reports. The drug GLB333 is an inhibitor of a cytokine that is involved in lupus. Globe Labs has indicated that the drug should be beneficial to treat lupus, due to its inhibitory action on cytokine or interleukin function. There are approximately 1,400,000 lupus patients in the United States according to the Scripps Magazine report (http://www.scripps.edu/philanthropy/lupus.html?origin=ggdislupus). To date there is no effective treatment availed for lupus sufferers. While the actual cause of the disease is not known, but the presence of cytokines or interleukins are well documented.

About lupus

Lupus, an autoimmune disease, happens when the immune system attacks its tissues, causing inflammation, swelling, pain, and damage. Lupus symptoms vary, and early lupus symptoms include fatigue, joint pain, fever, and a lupus rash, especially after being in the sun. Familiarize yourself with pictures of the lupus rash. Doctors diagnose lupus by symptoms and blood tests. Lupus is not contagious but has a hereditary component. For information, please visit the lupus Foundation of America (http://www.lupus.org/newsite/index.html).

About National Pharmaceuticals Corp.

National Pharmaceuticals Corp. is a Pharmaceutical Research and Development Corporation focused on leading edge technologies for treatment of human diseases. The company has embarked into the business of licensing mid stage development drugs for further development and marketing worldwide.

Forward-looking Statements - Important Information about Forward-Looking Statements in this press release is within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above.

Contact Information

  • National Pharmaceuticals Corp.
    Elaine Affleck
    (954) 903-1967